Skip Navigation



JAC Advance Access published online on September 26, 2008

Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn398
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/6/1301    most recent
dkn398v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Loeffler, A.
Right arrow Articles by Lloyd, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loeffler, A.
Right arrow Articles by Lloyd, D. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

In vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets

A. Loeffler1,*, S. J. Baines1, M. S. Toleman1, D. Felmingham2, S. K. Milsom1, E. A. Edwards1 and D. H. Lloyd1

1 Department of Veterinary Clinical Sciences, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Hertfordshire AL9 7TA, UK 2 Microbiology, Quotient Bioresearch, 7-9 William Road, London NW1 3ER, UK

Received 16 May 2008; returned 18 July 2008; revised 17 August 2008; accepted 29 August 2008


* Corresponding author. Tel: +44-1707-666234; Fax: +44-1707-666298; E-mail: aloeffler{at}rvc.ac.uk

Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) and multiresistant Staphylococcus pseudintermedius (MRSP) have emerged as important pathogens in animal infections. Associated therapeutic problems and the zoonotic potential of staphylococci have renewed interest in topical antibiotics for treatment and carrier decolonization. Fusidic acid and mupirocin are used topically in humans and animals but resistant strains isolated from people are increasing. This study investigates the in vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets.

Methods: A collection of 287 staphylococci was examined, comprising 102 MRSA, 102 methicillin-susceptible S. aureus, 71 S. pseudintermedius and 12 MRSP from canine and feline infections and carrier sites isolated in the UK and Germany. MICs were determined by the agar dilution method according to CLSI (formerly NCCLS) standards.

Results: The majority (89.7%) of all MICs were ≤0.25 mg/L. High MICs were observed for seven MRSA isolates (five with an MIC of fusidic acid of 512 mg/L, one with an MIC of fusidic acid of 1024 mg/L and one with with an MIC of mupirocin of 16 mg/L). MICs of both antibiotics were ≤2 mg/L for all MRSP. Infection isolates had higher MICs than those isolated from carriage sites for both antibiotics (P ≤ 0.001).

Conclusions: In all but seven MRSA isolates, MICs were below the concentrations achievable experimentally at application sites suggesting therapeutic efficacy of both antibiotics in infections involving multiresistant staphylococci and for decolonization of carriers. However, the seven MRSA with high MICs, all of the dominant UK human hospital lineages, highlight the importance of monitoring treatment success as resistant strains may occur in animals.

Key Words: MRSA , multiresistant , Staphylococcus pseudintermedius , dog , cat


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.